Bile acids play critical physiological roles in lipid emulsification and in cholesterol elimination from the body. However, excessive hepatic accumulation of bile acids can lead to cholestatic liver injury. A decade ago, a major breakthrough in the bile acid research field occurred with the identification of the nuclear receptors responsible for feedback regulation of bile acid synthesis. Small heterodimer partner (SHP) was found to inhibit the expression of the rate limiting bile acid synthetic enzymes Cyp7a1 and Cyp8b1, as demonstrated by the first SHP-/- mice, which were generated by the PI. Our recent studies of hepatic SHP regulation have revealed the importance of a protein-protein interaction with B-cell lymphoma protein 2 (Bcl-2). Subsequent RNA-seq studies using our new liver Bcl-2 overexpressed mice identified a critical role for the long non-coding RNA (lncRNA) H19 in cholestatic liver fibrosis. H19 has been implicated in liver cancer, yet very little is know about its physiological and molecular action in liver diseases. The proposed investigation of the Bcl-2/SHP/H19 axis represents a pioneering study in integrating bile acid signaling with nuclear receptor regulation of H19 expression and function. The overall objective is to understand the role of lncRNA H19 in regulating bile acid homeostasis and the development of cholestatic liver fibrosis involving Bcl-2 and SHP. The central hypothesis is that Bcl-2 functions as a molecular switch to dictate H19 induction of cholestasis and liver fibrosis through SHP-mediated bile acid signaling.
Aim #1 : To uncover a critical pathophysiological role of Bcl- 2 in bile acid homeostasis;
Aim #2 : To reveal a crucial regulatory function of H19 in cholestatic liver fibrosis;
and Aim #3 : To define the signaling pathways that make H19 a bile acid sensor. The experiments proposed build on our long-standing experience in studying bile acid metabolism and regulation of gene expression, and the development and appropriate use of knockout and transgenic mouse models. Accordingly, our laboratory is uniquely poised to identify and validate a novel lncRNA H19 regulatory module in the bile acid signaling pathway. This is of great potential human relevance, because H19 expression is highly induced in various human fibrotic and cirrhotic liver specimens. Thus, the mechanistic insights elucidated through the proposed research may pave the way for the development of therapeutic strategies to specifically down regulate H19 and diminish H19 promotion of cholestatic fibrosis.

Public Health Relevance

Disruption of bile acid homeostasis is closely associated with the development of cholestatic liver fibrosis and other chronic liver diseases in the United States. Long non-coding (lnc) RNAs are being increasingly recognized to have a profound impact in our understanding of disease pathobiology and leading to the emergence of new concepts underlying human diseases. This study will uncover for the first time the role of lncRNA in bile acid metabolism mediated by nuclear receptor signaling.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK104656-04
Application #
9435117
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Burgess-Beusse, Bonnie L
Project Start
2015-03-01
Project End
2019-02-28
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Connecticut
Department
Physiology
Type
Schools of Arts and Sciences
DUNS #
614209054
City
Storrs-Mansfield
State
CT
Country
United States
Zip Code
06269
Zhang, Li; Yang, Zhihong; Trottier, Jocelyn et al. (2017) Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay. Hepatology 65:604-615
Zhao, Yulan; Yang, Zhihong; Wu, Jianguo et al. (2017) High-mobility-group protein 2 regulated by microRNA-127 and small heterodimer partner modulates pluripotency of mouse embryonic stem cells and liver tumor initiating cells. Hepatol Commun 1:816-830
Yang, Zhihong; Ross, Ruth A; Zhao, Shi et al. (2017) LncRNA AK054921 and AK128652 are potential serum biomarkers and predictors of patient survival with alcoholic cirrhosis. Hepatol Commun 1:513-523
Liu, Chune; Yang, Zhihong; Wu, Jianguo et al. (2017) lncRNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis. Hepatology :
Song, Yongfeng; Liu, Chune; Liu, Xia et al. (2017) H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule. Hepatology 66:1183-1196
Tran, Melanie; Lee, Sang-Min; Shin, Dong-Ju et al. (2017) Loss of miR-141/200c ameliorates hepatic steatosis and inflammation by reprogramming multiple signaling pathways in NASH. JCI Insight 2:
Tran, Melanie; Wang, Li (2017) Preserving LXR by inhibiting T39: A step closer to treating atherosclerosis and steatohepatitis? Hepatology 65:741-744
Liangpunsakul, Suthat; Toh, Evelyn; Ross, Ruth A et al. (2017) Quantity of alcohol drinking positively correlates with serum levels of endotoxin and markers of monocyte activation. Sci Rep 7:4462
Choiniere, Jonathan; Wu, Jianguo; Wang, Li (2017) Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol 91:189-196
Wang, Li; Liangpunsakul, Suthat (2016) Circadian clock control of hepatic lipid metabolism: role of small heterodimer partner (Shp). J Investig Med 64:1158-61

Showing the most recent 10 out of 19 publications